Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Clear all

Conditions: Prostatic Neoplasms
Interventions: 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 1,144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 67
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 49 more

Conditions: Melanoma, Prostate Adenocarcinoma
Interventions: PEG-BCT-100; Biological
Lead sponsor: Bio-Cancer Treatment International Limited; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: San Diego, California • Santa Monica, California

Conditions: Impotence, Prostate Cancer
Interventions: GPI 1485; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 40 Years to 69 Years · Male only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 25
States / cities: Phoenix, Arizona • La Mesa, California • Stanford, California + 19 more

Conditions: Adenocarcinoma of the Prostate
Interventions: HR-A, HR-B; Radiation
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Prostate Adenocarcinoma, PSA Level Greater Than 0.2, PSA Level Greater Than or Equal to Two, PSA Progression, Recurrent Prostate Carcinoma
Interventions: Computed Tomography, Fluorine F 18 DCFPyL, Laboratory Biomarker Analysis, Positron Emission Tomography; Procedure · Radiation · Other
Lead sponsor: Andrei Iagaru; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Malignant Mesothelioma, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Thymoma and Thymic Carcinoma
Interventions: educational intervention, psychosocial assessment and care, quality-of-life assessment; Other · Procedure
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Fatigue, Metastatic Prostate Carcinoma, Sedentary Lifestyle, Stage IV Prostate Cancer AJCC (American Joint Committee on Cancer) v8, Stage IVA Prostate Cancer AJCC (American Joint Committee on Cancer) v8, Stage IVB Prostate Cancer AJCC (American Joint Committee on Cancer) v8
Interventions: Creatine Monohydrate, Exercise Intervention, Questionnaire Administration; Dietary Supplement · Behavioral · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Prostate Cancer
Interventions: docetaxel, leuprolide acetate, radiation therapy; Drug · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Raleigh, North Carolina

Conditions: Prostate Cancer
Interventions: hypofractionation; Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: Interviews; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 40 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer, Adenocarcinoma of the Prostate Stage I, Adenocarcinoma of the Prostate Stage II, Adenocarcinoma of the Prostate Stage III
Interventions: Magnetic Resonance Imaging; Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer, Advanced Cancer
Interventions: Radium-223, 177Lu-DOTATATE, 177Lu-PSMA-617; Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: Preference Based Decision Aid; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Male only
Enrollment: 743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: Castration-resistant Prostate Cancer, Stage IV Prostate Cancer
Interventions: abiraterone acetate; Drug
Lead sponsor: University of Chicago; Other
Eligibility: Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Evanston, Illinois + 2 more

Conditions: Prostate Cancer
Interventions: 18F-DCFBC; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer, Prostate Cancer Metastatic, Prostate Adenocarcinoma
Interventions: Relugolix Pill, Ritonavir, Itraconazole; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostatic Neoplasms
Interventions: VT-122, Placebo; Drug
Lead sponsor: Vicus Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 16
States / cities: Fayetteville, Arkansas • Santa Rosa, California • Parker, Colorado + 13 more

Conditions: Prostate Cancer
Interventions: Apalutamide, Leuprolide, Prednisone, Abiraterone Acetate; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 4
States / cities: La Jolla, California • Boston, Massachusetts • New York, New York

Conditions: Prostate Cancer
Interventions: Immediate Guided Lifestyle Program Intervention; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Male only
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions: placebo, gamma-secretase/Notch signalling pathway inhibitor RO4929097, bicalutamide; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Prostate Cancer, Urinary Tract Infection, Clostridium Difficile
Interventions: Ciprofloxacin; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Male only
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Breast Neoplasm, Prostatic Neoplasm, Colorectal Neoplasms, Endometrial Neoplasms, Hodgkin Disease, Non Hodgkin Lymphoma
Interventions: AH-HA Tool in the EPIC EHR; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 645 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 12
States / cities: Fort Smith, Arkansas • Cedar Rapids, Iowa • Ballwin, Missouri + 8 more

Search by objective public record fields.

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors

Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy

Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer

F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer

Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer

Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients

Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer

Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

iCCARE Project #4: Grounded Theory Study of the Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men Diagnosed With Prostate Cancer

Follow-Up Study for Men Diagnosed With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program

Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

Treatment Preference and Patient Centered Prostate Cancer Care

Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer

Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer

Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors

Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer

Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy

Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors